Previous Close | 212.20 |
Open | 183.93 |
Bid | 185.50 |
Ask | 191.75 |
Strike | 370.00 |
Expire Date | 2025-01-17 |
Day's Range | 183.93 - 185.20 |
Contract Range | N/A |
Volume | |
Open Interest | 96 |
The company entered into a buyout agreement with Eli Lilly.
(Bloomberg) -- A well-timed options trade in Point Biopharma Global Inc. stands to hand some investors upwards of $500,000 after Eli Lilly & Co.’s agreement to acquire the company sent its stock surging.Most Read from BloombergKey Taiwan Tech Firms Helping Huawei With China Chip PlantsWhy a US Recession Is Still Likely — and Coming SoonAirbnb Is Fundamentally Broken, Its CEO Says. He Plans to Fix It.Stocks, Bonds Sell Off as Volatility Makes Return: Markets WrapJPMorgan’s Dimon Predicts 3.5-Day
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.